Related references
Note: Only part of the references are listed.Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
Neeraj Gupta et al.
CLINICAL PHARMACOKINETICS (2019)
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
Michael J. Palte et al.
ADVANCES IN THERAPY (2019)
Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome
Renato Mantegazza
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
Naveed Shaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea
Joseph S. Dillon et al.
FUTURE ONCOLOGY (2018)
The expanding role of prodrugs in contemporary drug design and development
Jarkko Rautio et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Development and Evaluation of Talazoparib Nanoemulsion for Systemic Therapy of BRCA1-mutant Cancer
Neelesh Kumar Mehra et al.
ANTICANCER RESEARCH (2018)
Crystal Structures and Thermodynamic Properties of New Atypical Antipsychotic Cariprazine and Its Hydrochloride
Jiali Ye et al.
CRYSTALLOGRAPHY REPORTS (2018)
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations
Tanay S. Samant et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease
Thomas Mueller
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib
David L. Hughes
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
L. E. Dockery et al.
ONCOTARGETS AND THERAPY (2017)
Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges
Paolo Cerreia Vioglio et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
Dolly A. Parasrampuria et al.
CLINICAL PHARMACOKINETICS (2016)
Supersaturation Potential of Salt, Co-Crystal, and Amorphous Forms of a Model Weak Base
Luis Almeida e Sousa et al.
CRYSTAL GROWTH & DESIGN (2016)
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
George G. Zhanel et al.
DRUGS (2016)
Overview of elagolix for the treatment of endometriosis
Gian Benedetto Melis et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax
David L. Hughes
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2016)
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies
Muhammad Baluom et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Crystal Structure and Solid-State Properties of 3,4-Diaminopyridine Dihydrogen Phosphate and Their Comparison with Other Diaminopyridine Salts
Nathalie Mahe et al.
CRYSTAL GROWTH & DESIGN (2013)
Pharmaceutical salts: A summary on doses of salt formers from the Orange Book
C. Saal et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Impact of preformulation on drug development
Sonali S. Bharate et al.
EXPERT OPINION ON DRUG DELIVERY (2013)
Use of pharmaceutical salts and cocrystals to address the issue of poor solubility
David P. Elder et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Polymorphs, Salts, and Cocrystals: What's in a Name?
Srinivasulu Aitipamula et al.
CRYSTAL GROWTH & DESIGN (2012)
Non-clinical toxicological considerations for pharmaceutical salt selection
Evan A. Thackaberry
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened
Michael J. Munchhof et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Analysis of Relationships Between Solid-State Properties, Counterion, and Developability of Pharmaceutical Salts
Peter Guerrieri et al.
AAPS PHARMSCITECH (2010)
Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death
Richard A. Zager et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book Database
G. Steffen Paulekuhn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Salt formation to improve drug solubility
Abu T. M. Serajuddin
ADVANCED DRUG DELIVERY REVIEWS (2007)
Drug delivery strategies for poorly water-soluble drugs
Alfred Fahr et al.
EXPERT OPINION ON DRUG DELIVERY (2007)
Drugs as materials:: Valuing physical form in drug discovery
CR Gardner et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Pharmaceutical evaluation of early development candidates the 100 mg-approach
S Balbach et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Salt selection and optimisation procedures for pharmaceutical new chemical entities
RJ Bastin et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2000)
Share Paper
